Sp-Cyclic AMPS (sodium salt) (Synonyms: Sp-cAMPS) |
| Catalog No.GC11125 |
Sp-Cyclic AMPS (sodium salt), a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 142439-95-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Sp-8-CPT-Cyclic AMPS (Sp-8-CPT-cAMPS) is a cell permeable cAMP analog that potently and selectively activates protein kinase A [1].
Protein kinase A, also known as cAMP-dependent protein kinase, is one of the most widely researched protein kinase. Protein kinase A phosphorylates proteins containing the motif Arginine-Arginine-X-Serine and activates or deactivates the proteins. Protein kinase A has been involved in regulation of glycogen, sugar, and lipid metabolism [2]. The effects of PKA activation vary with cell type. Protein kinase A has been implicated in muscular system, cardiovascular, and nervous system.
Sp-8-CPT-cAMPS is a structural combination of the lipophilic and non-hydrolyzable cAMP analogs 8-CPT-Cyclic AMP and Sp-Cyclic AMPS. Sp-8-CPT-cAMPS is used to investigate the effects of cAMP-dependent PKA signaling [1]. In guinea-pig trachealis, treatment with 10 μM Sp-8-CPT-cAMPS for 30 min reduced the spasmogenic response with the pEC50 value of 4.74 [3].
References:
[1] Dostmann W R, Taylor S S, Genieser H G, et al. Probing the cyclic nucleotide binding sites of cAMP-dependent protein kinases I and II with analogs of adenosine 3', 5'-cyclic phosphorothioates[J]. Journal of Biological Chemistry, 1990, 265(18): 10484-10491.
[2] Hanks S K, Quinn A M, Hunter T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains[J]. Science, 1988, 241(4861): 42-52.
[3] Spicuzza L, Belvisi M G, Birrell M A, et al. Evidence that the anti‐spasmogenic effect of the β‐adrenoceptor agonist, isoprenaline, on guinea‐pig trachealis is not mediated by cyclic AMP‐dependent protein kinase[J]. British journal of pharmacology, 2001, 133(8): 1201-1212.
| Cas No. | 142439-95-0 | SDF | |
| Synonyms | Sp-cAMPS | ||
| Chemical Name | cyclic 3',5'-[hydrogen (S)-phosphorothioate] adenosine, monosodium salt | ||
| Canonical SMILES | [S-][P@]1(OC[C@]2([H])[C@@]([C@@H](O)[C@H](N3C(N=CN=C4N)=C4N=C3)O2)([H])O1)=O.[Na+] | ||
| Formula | C10H11N5O5PS • Na | M.Wt | 367.3 |
| Solubility | ≤25mg/ml in Water | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7226 mL | 13.6129 mL | 27.2257 mL |
| 5 mM | 0.5445 mL | 2.7226 mL | 5.4451 mL |
| 10 mM | 0.2723 mL | 1.3613 mL | 2.7226 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 37 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *